Agios' first-in-class PK activator Pyrukynd scores FDA approval to treat rare blood disorder
17th February 2022 Uncategorised 0 Agios’ first-in-class PK activator Pyrukynd scores FDA approval to treat rare blood disorder
esagonowsky
Thu, 02/17/2022 – 16:45
More: Agios' first-in-class PK activator Pyrukynd scores FDA approval to treat rare blood disorder
Source: fierce